DEF: Marker Therapeutics Seeks Share Increase Amidst Losses

Marker Therapeutics, Inc. will hold its Annual Meeting on May 1, 2026, seeking stockholder approval for a significant increase in authorized common stock and executive compensation.

Summary

• The Annual Meeting of Stockholders is scheduled for May 1, 2026, at 10:00 a.m. Eastern Time, to be held virtually.
• Stockholders will vote on the election of five director nominees.
• An advisory vote on the compensation of named executive officers is on the agenda.
• A proposal to increase authorized common stock from 30,000,000 to 130,000,000 shares will be voted upon.
• A proposal to amend the Certificate of Incorporation to revise the voting threshold for common stock increases or decreases to align with Delaware law (majority of votes cast) is included.
• The ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is also on the ballot.
• A proposal to approve the adjournment of the Annual Meeting in the event that votes for the authorized common stock increase (Proposal 3) are insufficient will be considered.
• As of the record date, March 10, 2026, there were 16,673,127 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to persistent negative net income, significant decline in Total Shareholder Return, and the explicit mention of substantial doubt about the company's ability to continue as a going concern, despite efforts to improve corporate governance and operational flexibility.

Positives

• The Board of Directors operates with an independent chair, reinforcing board independence and objective oversight of management.
• The company has adopted a Code of Business Conduct and Ethics and Corporate Governance Guidelines to ensure ethical standards and effective oversight.
• The Board is committed to diversity and inclusion, actively considering gender, racial, and ethnic diversity in its director selection process.

Negatives

• Net income has been consistently negative and worsened over the past three fiscal years, reporting $(8.24) million in 2023, $(10.73) million in 2024, and $(12.16) million in 2025.
• Total Shareholder Return (TSR) for a $100 investment declined significantly from $206.84 in 2023 to $56.55 in 2024, and further to $47.91 in 2025, indicating substantial value erosion.
• The former independent registered public accounting firm, Marcum LLP, included an explanatory paragraph in its report regarding substantial doubt about the company's ability to continue as a going concern.
• The company faces challenges in securing sufficient stockholder votes for charter amendments due to low retail investor turnout, necessitating a proposal to lower the voting threshold.

Risks

• There is substantial doubt about the company's ability to continue as a going concern, as noted in the former auditor's report.
• Approval of Proposal 3, which seeks to increase authorized common stock, could facilitate future efforts by the company to deter or prevent changes in control, potentially at a premium for stockholders.
• The difficulty in securing a majority of outstanding shares for certain charter amendments, particularly from retail investors, poses a risk to the company's ability to implement future corporate actions like increasing authorized shares or effecting reverse stock splits.
• The Compensation Committee assesses and monitors whether any of the company's compensation policies and programs have the potential to encourage excessive risk-taking.

Future Outlook

The company intends to use the additional authorized shares, if approved, for future business and financial purposes, including raising capital, providing equity incentives to employees, officers, or directors, establishing strategic relationships, and expanding its business or pipeline through acquisitions. The Board believes the proposed amendment to adjust voting requirements for charter amendments is critical for future flexibility in increasing or decreasing authorized shares or implementing reverse stock splits.

Management Comments

• The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting.
• The Company believes that separation of the positions of Board Chair and Chief Executive Officer reinforces the independence of the Board in its oversight of the business and affairs of the Company.
• The Company believes that having an independent Board Chair creates an environment that is more conducive to objective evaluation and oversight of managements performance, increasing management accountability and improving the ability of the Board to monitor whether managements actions are in the best interests of the Company and its stockholders.
• The Company believes that having an independent Board Chair can enhance the effectiveness of the Board as a whole.
• The Company believes it could face significant challenges in securing the vote of the holders of a majority of the outstanding shares of its common stock in the future.
• The Board of Directors has concluded that, due to the difficulty of securing the stockholder vote to increase the authorized shares of common stock under the current charter, it is advisable and in the best interests of the stockholders to amend the Companys charter to align the existing voting threshold with DGCL Section 242(d)(2).
• The Board believes that the current voting requirement effectively gives disproportionate influence to stockholders who fail to vote on these matters, as their non-votes have the same effect as votes against a proposal to approve such matters.
• This is inconsistent with fundamental principles of corporate democracy, where decisions should be made by those stockholders who choose to participate in the voting process.
• The Voting Requirement Amendment would ensure that corporate decisions are made by engaged stockholders who actually cast votes, rather than being determined by stockholder apathy or the practical difficulties of share lending and foreign ownership structures.
• Our Board of Directors believes the proposed amendment to align the voting thresholds for the matters described above with Section 242(d)(2) of the DGCL is critical to ensuring that the Company is able to increase or decrease its authorized shares, or implement reverse stock splits, in the future if necessary.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry often requires significant capital for R&D and clinical trials, making the ability to raise capital and offer equity incentives crucial. The proposed increase in authorized shares and adjustment to voting thresholds reflect a common challenge for smaller public companies, particularly those with a high retail investor base, in navigating corporate governance requirements to ensure operational flexibility and strategic growth. The negative net income and declining TSR suggest the company is in a development phase or facing significant market pressures, common for early-stage or struggling biotech firms.

Comparison to Industry Standards

• StockSavvy.ai observes that the company's negative net income and declining Total Shareholder Return (TSR) over the past three years (2023-2025) are significantly below the performance of established, profitable biopharmaceutical companies like Johnson & Johnson (JNJ) or Pfizer (PFE), which typically demonstrate consistent revenue growth and positive earnings.
• The need to increase authorized shares from 30 million to 130 million, coupled with the proposal to lower the voting threshold for such changes, suggests a potential struggle to attract and retain institutional investor support or a reliance on retail investors, which can be less common for mature, stable industry players.
• The 'going concern' explanatory paragraph in the former auditor's report is a red flag, indicating financial instability that is not typically seen in industry leaders, but can be common for smaller, clinical-stage biotech companies.
• The executive compensation structure, heavily reliant on equity awards (e.g., Dr. Vera's 2025 incentive paid in stock options), aligns with common practices in the biotech sector where long-term value creation is incentivized, but the declining TSR indicates a disconnect between compensation incentives and shareholder returns.

Management Changes

Corporate Governance

Related Party Transactions

• Purchased $277,000 of cell culture devices from Wilson Wolf Manufacturing Corporation in 2023, a company whose CEO, John Wilson, was a former director. No purchases were made in 2025.
• Sold manufacturing facilities, equipment, and related contracts to Cell Ready, LLC for $19.0 million on June 26, 2023. Cell Ready is owned by former director John Wilson.
• Entered into a Master Services Agreement (MSA) with Cell Ready, LLC on February 22, 2024, for manufacturing services for clinical trials (Marker MT-401 and/or MT-601).
• Paid Cell Ready approximately $1.3 million in 2023 and $5.5 million in 2024 for outsourced product development and manufacturing services.
• Mutually terminated the MSA with Cell Ready on March 27, 2025, with a settlement payment of approximately $453,000 to Cell Ready.
• Provided development services to AlloVir, Inc. until June 2023, where Juan Vera (CEO) served on the board of directors.

Stakeholder Impact

• Shareholders face potential dilution from the proposed increase in authorized shares (Proposal 3), but this also provides the company with flexibility for future capital raises and strategic transactions. The proposed change in voting rights for certain charter amendments (Proposal 4) could alter the influence of non-voting shares. The negative financial performance (net income, TSR) has negatively impacted shareholder value.
• Employees, officers, and directors are significantly impacted by the company's equity incentive programs, which are designed to align their interests with long-term value creation. Management changes and compensation details are transparently disclosed.
• The termination of the Master Services Agreement with Cell Ready indicates a shift in manufacturing strategy, which could impact Cell Ready as a former key supplier.
• Creditors may view the 'going concern' explanatory paragraph from the former auditor as a significant concern regarding the company's financial stability and ability to meet future obligations.

Next Steps

• Annual Meeting of Stockholders on May 1, 2026, to vote on the proposed resolutions.
• If Proposal 3 (increase authorized common stock) is approved, the company will file a Certificate of Amendment with the Delaware Secretary of State.
• If Proposal 4 (adjust voting requirements) is approved, the company will file a Certificate of Amendment with the Delaware Secretary of State.
• Final voting results will be published in a Current Report on Form 8-K within four business days after the Annual Meeting.
• The next scheduled advisory vote on executive compensation ('say-on-pay') will be held at the 2027 Annual Meeting.
• Stockholder proposals for the next Annual Meeting are due between December 31, 2026, and January 29, 2027.

Key Dates

Recommendation

The company exhibits significant financial distress, evidenced by persistent and worsening negative net income over the past three years, coupled with a drastic decline in Total Shareholder Return. The former auditor's 'going concern' warning is a critical red flag. While the proposal to increase authorized shares could facilitate future capital raises, it also signals potential dilution and a pressing need for funding, which, given the current financial performance, may not translate into shareholder value. The proposed change in voting thresholds, while aimed at operational efficiency, also suggests difficulty in gaining broad shareholder consensus, further highlighting underlying issues. A seasoned investor would likely view these factors as strong indicators of high risk and poor investment prospects.

Keywords

Marker Therapeutics, Proxy Statement, SEC Filing, Corporate Governance, Stockholder Meeting, Authorized Shares, Common Stock, Executive Compensation, Board of Directors, Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, Related Party Transactions, Financial Performance, Net Income, TSR, Biopharmaceutical, Life Sciences, Share Dilution, Capital Raise